Ali Dheyaa Marsool Marsool

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Idiopathic Pulmonary Fibrosis

Top Venues

Health science reports

Immunity, inflammation and disease

This page only lists publications with an associated author ORCID identifier.

Publications

Abdullah Muataz Taha Al-Ibraheem, Al-Tuaama Abdullah Zeyad Hameed, Mohammed Dheyaa Marsool Marsool, Hritvik Jain, Priyadarshi Prajjwal, Istevan Khazmi, Ridha Saad Nazzal, Hussein Mezher Hameed Al-Najati, Baqer Hadi Yusur Kharibet Al-Zuhairi, Maryam Razzaq, Zainab Baqir Abd, Ali Dheyaa Marsool Marsool, Abdulrahman Isam Wahedaldin, Omniat Amir Hussin
Exercise-Induced cytokines, diet, and inflammation and their role in adipose tissue metabolism. Health science reports 7 (9) (2024)
Abdullah Muataz Taha Al-Ibraheem, Al-Tuaama Abdullah Zeyad Hameed, Mohammed Dheyaa Marsool Marsool, Hritvik Jain, Priyadarshi Prajjwal, Istevan Khazmi, Ridha Saad Nazzal, Hussein Mezher Hameed Al-Najati, Baqer Hadi Yusur Kharibet Al-Zuhairi, Maryam Razzaq, Zainab Baqir Abd, Ali Dheyaa Marsool Marsool, Abdulrahman Isam Wahedaldin, Omniat Amir Hussin
Exercise-Induced cytokines, diet, and inflammation and their role in adipose tissue metabolism. Health science reports 7 (9) (2024)
Dalia D Hadi, Mohammed Dheyaa Marsool Marsool, Ali Dheyaa Marsool Marsool, Neel Vora, Sajjad G Al-Badri, Nabeel H K Al-Fatlawi, Ameer F Abbas Al Wssawi, Abdullah M T Al-Ibraheem, Khadija A Hamza, Priyadarshi Prajjwal, Mohammed A Mateen, Omniat Amir Hussin
Idiopathic pulmonary fibrosis: Addressing the current and future therapeutic advances along with the role of Sotatercept in the management of pulmonary hypertension. Immunity, inflammation and disease 11 (11) (2023)
Priyadarshi Prajjwal, Mohammed Dheyaa Marsool Marsool, Shahnaz Asharaf, Pugazhendi Inban, Srikanth Gadam, Rukesh Yadav, Neel Vora, Varsha Nandwana, Ali Dheyaa Marsool Marsool, Omniat Amir Hussin
Comparison of recent updates in genetics, immunology, biomarkers, and neuroimaging of primary-progressive and relapsing-remitting multiple sclerosis and the role of ocrelizumab in the management of their refractory cases. Health science reports 6 (7) (2023)